ArticleWorld journal of surgical oncology2026
Differential expression of estrogen and progesterone receptors before and after surgery in endometrial cancer and analysis of recurrence prediction model.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer has rising incidence and mortality, with high recurrence rates (10%-70%) post-surgery. Discrepancies between preoperative biopsy and postoperative pathology, particularly in estrogen receptor (ER) and progesterone receptor (PR) expression, may misguide treatment. This single-center study explored ER/PR expression dynamics pre- and post-surgery and developed a recurrence prediction model for clinical reference in comparable settings.
methodsA retrospective cohort of 600 stage I-III endometrial cancer patients (2017-2021) exclusively from a single center was analyzed. Preoperative biopsies (blind vs. hysteroscopy-guided) and postoperative specimens underwent ER/PR immunohistochemical testing. Concordance was assessed via Cohen's kappa. Survival analysis (Kaplan-Meier), ROC curves, and Cox regression identified prognostic factors. A nomogram integrating PR expression dynamics and clinicopathological parameters was developed and validated.
resultsER and PR expression showed moderate-to-substantial overall concordance (86.8%, κ = 0.481; 87.1%, κ = 0.676), with hysteroscopy-guided biopsies demonstrating superior agreement (ER: 94.0%, κ = 0.733; PR: 91.4%, κ = 0.742) versus blind biopsies. Combined pre-/postoperative PR expression improved recurrence prediction (AUC = 0.680). The integrated nomogram (AUC = 0.864) effectively stratified high-risk patients (3-year recurrence-free survival: 53.40% vs. 86.05% in non-high-risk), who benefited from adjuvant therapy.
conclusionsHysteroscopy-guided biopsy enhances ER/PR assessment accuracy. The nomogram integrating PR dynamics and clinical parameters enables precise recurrence risk stratification, aiding personalized adjuvant therapy decisions in similar clinical settings.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.